93 related articles for article (PubMed ID: 33905671)
1. NPRL2 reduces the niraparib sensitivity of castration-resistant prostate cancer via interacting with UBE2M and enhancing neddylation.
Zhao X; Jiang L; Hu D; Tang Y; Zhao G; Du X; Luo S; Tang W
Exp Cell Res; 2021 Jun; 403(2):112614. PubMed ID: 33905671
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
Wang X; Chen C; Vuong D; Rodriguez-Rodriguez S; Lam V; Roleder C; Wang JH; Kambhampati S; Berger A; Pennock N; Torka P; Hernandez-Ilizaliturri F; Siddiqi T; Wang L; Xia Z; Danilov AV
Leukemia; 2023 Jun; 37(6):1324-1335. PubMed ID: 37031300
[TBL] [Abstract][Full Text] [Related]
3. Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report.
Inno A; Picece V; Bogina G; Settanni G; Viassolo V; Salgarello M; Gori S
Clin Lung Cancer; 2024 Mar; 25(2):175-179. PubMed ID: 38008640
[No Abstract] [Full Text] [Related]
4. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
5. Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy.
Valabrega G; Scotto G; Tuninetti V; Pani A; Scaglione F
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921561
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
Ai X; Pan Y; Shi J; Yang N; Liu C; Zhou J; Zhang X; Dong X; He J; Li X; Chen G; Li X; Zhang H; Liao W; Zhang Y; Ma Z; Jiang L; Cui J; Hu C; Wang W; Huang C; Zhao J; Ding C; Hu X; Wang K; Gao B; Song Y; Liu X; Xiong J; Liu A; Li J; Liu Z; Li Y; Wang M; Zhang B; Zhang D; Lu S
J Thorac Oncol; 2021 Aug; 16(8):1403-1414. PubMed ID: 33915252
[TBL] [Abstract][Full Text] [Related]
7. RETRACTED: A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells.
Mukherjee J; Pandita A; Kamalakar C; Johannessen TC; Ohba S; Tang Y; Dalle-Ore CL; Bjerkvig R; Pieper RO
Sci Transl Med; 2021 May; 13(592):. PubMed ID: 33952676
[TBL] [Abstract][Full Text] [Related]
8. mTOR signaling regulates gastric epithelial progenitor homeostasis and gastric tumorigenesis via MEK1-ERKs and BMP-Smad1 pathways.
Li K; Wu H; Wang A; Charron J; Mishina Y; Habib SL; Liu H; Li B
Cell Rep; 2021 May; 35(5):109069. PubMed ID: 33951440
[TBL] [Abstract][Full Text] [Related]
9. TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models.
Wang L; Zhu X; Li L; Li L; Fu L; Li Y; Fu H; Chen X; Lou L
Am J Cancer Res; 2021; 11(4):1632-1645. PubMed ID: 33948378
[TBL] [Abstract][Full Text] [Related]
10. TFG binds LC3C to regulate ULK1 localization and autophagosome formation.
Carinci M; Testa B; Bordi M; Milletti G; Bonora M; Antonucci L; Ferraina C; Carro M; Kumar M; Ceglie D; Eck F; Nardacci R; le Guerroué F; Petrini S; Soriano ME; Caruana I; Doria V; Manifava M; Peron C; Lambrughi M; Tiranti V; Behrends C; Papaleo E; Pinton P; Giorgi C; Ktistakis NT; Locatelli F; Nazio F; Cecconi F
EMBO J; 2021 May; 40(10):e103563. PubMed ID: 33932238
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative and antimetastatic characterization of an exo-heterocyclic androstane derivative against human breast cancer cell lines.
Kulmány ÁE; Frank É; Kovács D; Kirisits K; Krupitza G; Neuperger P; Alföldi R; Puskás LG; Szebeni GJ; Zupkó I
Biomed Pharmacother; 2021 Aug; 140():111728. PubMed ID: 34020244
[TBL] [Abstract][Full Text] [Related]
12. Disease-causing mutated ATLASTIN 3 is excluded from distal axons and reduces axonal autophagy.
Behrendt L; Hoischen C; Kaether C
Neurobiol Dis; 2021 Jul; 155():105400. PubMed ID: 34019998
[TBL] [Abstract][Full Text] [Related]
13. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
[TBL] [Abstract][Full Text] [Related]
14. UHRF1 regulates the transcriptional repressor HBP1 through MIF in T acute lymphoblastic leukemia.
Yao J; Luo Y; Zeng C; He H; Zhang X
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34013373
[TBL] [Abstract][Full Text] [Related]
15. Carney Triad, Carney-Stratakis Syndrome, 3PAS and Other Tumors Due to SDH Deficiency.
Pitsava G; Settas N; Faucz FR; Stratakis CA
Front Endocrinol (Lausanne); 2021; 12():680609. PubMed ID: 34012423
[TBL] [Abstract][Full Text] [Related]
16. A PKD-MFF signaling axis couples mitochondrial fission to mitotic progression.
Pangou E; Bielska O; Guerber L; Schmucker S; Agote-Arán A; Ye T; Liao Y; Puig-Gamez M; Grandgirard E; Kleiss C; Liu Y; Compe E; Zhang Z; Aebersold R; Ricci R; Sumara I
Cell Rep; 2021 May; 35(7):109129. PubMed ID: 34010649
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial.
Marandino L; Raggi D; Calareso G; Alessi A; Colecchia M; Martini A; Briganti A; Montorsi F; Madison R; Ross JS; Necchi A
Clin Genitourin Cancer; 2021 Oct; 19(5):457-465. PubMed ID: 34006499
[TBL] [Abstract][Full Text] [Related]
18. The Absence of PTEN in Breast Cancer Is a Driver of MLN4924 Resistance.
Du MG; Peng ZQ; Gai WB; Liu F; Liu W; Chen YJ; Li HC; Zhang X; Liu CH; Zhang LQ; Jiang H; Xie P
Front Cell Dev Biol; 2021; 9():667435. PubMed ID: 33996822
[No Abstract] [Full Text] [Related]
19. EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer.
Liu X; Adorno-Cruz V; Chang YF; Jia Y; Kawaguchi M; Dashzeveg NK; Taftaf R; Ramos EK; Schuster EJ; El-Shennawy L; Patel D; Zhang Y; Cristofanilli M; Liu H
Theranostics; 2021; 11(13):6632-6643. PubMed ID: 33995681
[TBL] [Abstract][Full Text] [Related]
20. DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells.
Bi Y; Chen X; Wei B; Wang L; Gong L; Li H; Xiong X; Zhao Y
Theranostics; 2021; 11(13):6355-6369. PubMed ID: 33995662
[No Abstract] [Full Text] [Related]
[Next] [New Search]
